Buy Crypto
Pay with
USD
USD
Buy & Sell
Hot
Supports Visa, Mastercard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Markets
Trade
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
U.S. Stocks
CFD
U.S. stock CFD derivatives
Futures
High leverage, 24/7 trading
Tokenized Stocks
Backed by real stock assets
GUSD
Mint GUSD for Treasury RWA yields
Earn
Launch
CandyDrop
tag
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investment
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
More
Promotions
AI
Others
TradFi
Rewards
Square
Latest
Hot
News
Profile
GateUser-4eae4cef

Related-party transactions, but the track is indeed a necessity—everyone wants a slice of the cake in innovative liver disease drugs.

View Original
MarsBitNews
Fosun Pharma: Plans to invest 414 million yuan to participate in the Series B financing and equity transfer of the liver disease innovative drug company Xingyao Kunze
Fosun Pharma announced that its controlling subsidiary, Fosun Pharma Industry, plans to participate in Xingyao Kunze’s Series B financing with RMB 414 million and acquire part of the equity held by its associate companies, the Suzhou Fund and the Tianjin Fund. RMB 218 million will be used to subscribe for RMB 2.9368 million of newly increased registered capital, and RMB 197 million will be used to acquire RMB 3.0865 million of existing registered capital. After the transaction is completed, it will hold 20.87% of Xingyao Kunze’s equity. The target company focuses on research and development of innovative drugs for liver diseases. This investment constitutes a related-party transaction, aiming to enrich the liver disease treatment pipeline.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments

  • Pinned

Sitemap